Inogen Inc (INGN) Stake Increased by American International Group Inc

Blair William & Co/il says it sold 21,188 shares in quarter ending 09/30/2017 decreasing its exposure to Inogen Inc by 2.5%. Its investment was worth $79,431,000 a decrease of 2.8% as of quarter end. SG Americas Securities LLC purchased a new position in shares of Inogen during the third quarter valued at about $116,000. As of the end of the quarter Ubs Asset Management Americas Inc had bought 253 shares growing its holdings by 3,162.5%. Blair William & Co/il divested its holdings by selling 21,188 shares a decrease of 2.5% in the quarter. Strs Ohio lifted its holdings in shares of Inogen by 4,476.0% during the 3rd quarter. Strs Ohio now owns 22,880 shares of the medical technology company's stock valued at $2,175,000 after purchasing an additional 22,380 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Inogen by 24.9% in the 2nd quarter. Curbstone Financial Management Corp now owns 22,460 shares of the medical technology company's stock valued at $2,136,000 after purchasing an additional 10,505 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This article was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was illegally copied and republished in violation of United States & worldwide copyright & trademark legislation.

Several research analysts recently commented on INGN shares. BidaskClub cut Inogen from a "strong-buy" rating to a "buy" rating in a report on Monday, July 31st. Needham & Company LLC increased their price target on Inogen from $108.00 to $125.00 and gave the stock a "strong-buy" rating in a report on Wednesday. Zacks Investment Research upgraded Inogen from a "hold" rating to a "buy" rating and set a $131.00 price target for the company in a report on Thursday.

September 12 investment analysts at Piper Jaffray Companies kept the company rating at "Hold" targeting a price of $90.00. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company's stock. The stock presently has a consensus rating of "Buy" and a consensus price target of $58.83.

Inogen, Inc (INGN) traded down $5.53 on Friday, reaching $114.19. The most current P/E ratio is 81.86 and the market cap of the company is 2.43B. Inogen, Inc has a 52 week low of $59.84 and a 52 week high of $124.90. The medical technology company reported $0.33 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.29 by $0.04. The firm had revenue of $54.42 million for the quarter, compared to the consensus estimate of $47.89 million. Inogen had a return on equity of 9.59% and a net margin of 7.70%. The firm's quarterly revenue was up 33.5% compared to the same quarter previous year. Inogen's quarterly revenue was up 26.8% compared to the same quarter last year. equities analysts anticipate that Inogen will post 1.19 earnings per share for the current fiscal year.

In related news, EVP Matt Scribner sold 2,500 shares of the company's stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $92.45, for a total value of $231,125.00. Following the sale, the executive vice president now owns 6,964 shares in the company, valued at approximately $643,821.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the company's stock in a transaction on Monday, October 16th. The stock was sold at an average price of $94.93, for a total value of $1,423,950.00.